Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Omar Hussain

Plastic Surgery Beverly Hills, CA Medical Doctor

NPI 1881987832 CMS profile 40676

8907 Wilshire Blvd Ste 100, Beverly Hills, CA 90211

Open in the dashboard

General payments

$3,729

138 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Omar Hussain of Beverly Hills, CA is reported in the CMS Open Payments database as having received $3,729 across 138 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $75 3
2024 General $302 11
2023 General $294 13
2022 General $872 21
2021 General $669 38
2020 General $302 15
2019 General $1,215 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Omar Hussain
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Omar Hussain were reported at $75. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Omar Hussain Plastic Surgery median Middle half National median
2019 $1,215 $371 $122–$1,483 $163
2020 $302 $158 $52–$438 $114
2021 $669 $249 $87–$752 $132
2022 $872 $274 $102–$793 $149
2023 $294 $299 $113–$891 $160
2024 $302 $361 $124–$1,062 $164
2025 $75 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $866 52 payments
  2. AbbVie, Inc. $608 24 payments
  3. Sientra, Inc. $526 4 payments
  4. Celularity, Inc. $382 7 payments
  5. Integra LifeSciences Corporation $366 13 payments
  6. Galderma Laboratories, L.P. $201 10 payments
  7. Misonix Inc $157 7 payments
  8. Merz North America, Inc. $155 6 payments
  9. Apyx Medical Corporation $146 2 payments
  10. Derma Sciences, Inc. $90 2 payments
  11. Other $231 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,729 138 payments
Products named General payments · program years 2019–2025
  1. BOTOX $723 40 payments
  2. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $526 4 payments
  3. BOTOX COSMETIC $305 18 payments
  4. INTEGRA WOUND MATRIX (IWM) $255 8 payments
  5. BILAYER WOUND MATRIX (BWM) $255 8 payments
  6. PRIMATRIX $233 10 payments
  7. IDRT $210 9 payments
  8. Xeomin $139 5 payments
  9. FLOWABLE $119 7 payments
  10. Biovance $114 1 payment
  11. Other $1,253 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

138 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record